Ginkgo Bioworks announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities. Ginkgo’s foundry automates and scales the process of organism engineering, allowing engineers to prototype thousands of biological designs. This evolving platform equips companies and labs from startups to large pharmaceutical companies with access to robust technology, without the need to invest in costly lab and R&D infrastructure in-house and aims to drive down the cost per design.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks, Esperovax announce partnership to develop circular RNAs
- Ginkgo Bioworks, MoH of Botswana enter MoU on biosecurity capabilities
- Cronos unveils new CBC product, Spinach FEELZ Day Trip Gummies
- Berenberg starts ‘well-positioned’ disruptor Ginkgo Bioworks with a Buy
- Ginkgo Bioworks initiated with a Buy at Berenberg